Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23500304)

1.

Pre-procedural estimate of individualized bleeding risk impacts physicians' utilization of bivalirudin during percutaneous coronary intervention.

Rao SC, Chhatriwalla AK, Kennedy KF, Decker CJ, Gialde E, Spertus JA, Marso SP.

J Am Coll Cardiol. 2013 May 7;61(18):1847-52. doi: 10.1016/j.jacc.2013.02.017. Epub 2013 Mar 7.

3.

Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.

Taylor LA, Mauro VF.

Ann Pharmacother. 2012 Jan;46(1):35-41. doi: 10.1345/aph.1Q402. Epub 2011 Dec 13.

PMID:
22170973
4.

Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.

Cortese B, Micheli A, Picchi A, Bandinelli L, Brizi MG, Severi S, Limbruno U.

Coron Artery Dis. 2009 Aug;20(5):348-53. doi: 10.1097/MCA.0b013e32832cff08.

PMID:
19543084
5.

Body mass index and bleeding complications after percutaneous coronary intervention: does bivalirudin make a difference?

Delhaye C, Wakabayashi K, Maluenda G, Belle L, Ben-Dor I, Gonzalez MA, Gaglia MA Jr, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R.

Am Heart J. 2010 Jun;159(6):1139-46. doi: 10.1016/j.ahj.2010.03.011.

PMID:
20569731
6.

Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).

Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G.

Am J Cardiol. 2012 Aug 15;110(4):478-84. doi: 10.1016/j.amjcard.2012.04.017. Epub 2012 May 12.

PMID:
22583760
7.

Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).

Parodi G, Migliorini A, Valenti R, Bellandi B, Signorini U, Moschi G, Buonamici P, Cerisano G, Antoniucci D.

Am J Cardiol. 2010 Apr 15;105(8):1053-9. doi: 10.1016/j.amjcard.2009.12.001. Epub 2010 Feb 20.

PMID:
20381652
8.

Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function.

Roguin A, Steinberg BA, Watkins SP, Resar JR.

Int J Cardiovasc Intervent. 2005;7(2):88-92.

PMID:
16093217
9.
10.

Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.

Steinberg DH, Shah P, Kinnaird T, Pinto Slottow TL, Roy PK, Okabe T, Bonello L, de Labriolle A, Smith KA, Torguson R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R.

Am J Cardiol. 2008 Jul 15;102(2):160-4. doi: 10.1016/j.amjcard.2008.03.030. Epub 2008 May 28.

PMID:
18602514
11.

Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.

Seybert AL.

Pharmacotherapy. 2002 Jun;22(6 Pt 2):112S-118S. Review.

PMID:
12064568
12.

Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.

Pinto DS, Ogbonnaya A, Sherman SA, Tung P, Normand SL.

Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):52-61. doi: 10.1161/CIRCOUTCOMES.111.961938. Epub 2012 Jan 10.

13.

Evaluation of bivalirudin hyper- and hypo-ACT responses in the setting of percutaneous coronary intervention.

Weeks PA, Alkhateeb HM, Michaud SE, Diez JG.

J Invasive Cardiol. 2013 May;25(5):250-3.

14.

Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention.

Bertrand OF, Jolly SS, Rao SV, Patel T, Belle L, Bernat I, Parodi G, Costerousse O, Mann T.

Am J Cardiol. 2012 Aug 15;110(4):599-606. doi: 10.1016/j.amjcard.2012.03.051. Epub 2012 May 15.

PMID:
22591669
16.

Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.

Feldman DN, Wong SC, Gade CL, Gidseg DS, Bergman G, Minutello RM.

Am Heart J. 2007 Oct;154(4):695-701. Epub 2007 Aug 20.

PMID:
17892994
17.
18.

Comparison of prolonged bivalirudin infusion versus intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with angina pectoris.

Cortese B, Picchi A, Micheli A, Ebert AG, Parri F, Severi S, Limbruno U.

Am J Cardiol. 2009 Oct 15;104(8):1063-8. doi: 10.1016/j.amjcard.2009.06.005.

PMID:
19801025
19.
20.

Safety and efficacy of prasugrel use in patients undergoing percutaneous coronary intervention and anticoagulated with bivalirudin.

Laynez A, Sardi G, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Lindsay J, Waksman R.

Am J Cardiol. 2013 Feb 15;111(4):516-20. doi: 10.1016/j.amjcard.2012.10.035. Epub 2012 Dec 4.

PMID:
23219177
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk